Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
This page archives news coverage for 89bio, Inc. (NASDAQ: ETNB), a former clinical-stage biopharmaceutical company that was acquired by Roche. Browse historical news to understand the company's drug development journey, clinical trial progress, and the events leading to its acquisition.
89bio focused on developing therapies for liver and cardio-metabolic diseases, with its lead candidate BIO89-100 targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The company's news history reflects the typical trajectory of a clinical-stage biotech: quarterly financial updates, clinical trial milestones, conference presentations, and ultimately, the announcement of its acquisition by a major pharmaceutical company.
For investors researching the NASH therapeutic landscape or tracking how clinical-stage biopharmaceutical acquisitions unfold, 89bio's news archive provides valuable context. The coverage documents earnings reports, business updates, and corporate developments from the company's founding through its transition to Roche ownership. Understanding this history may inform analysis of similar companies pursuing metabolic disease treatments.
Note that as an acquired company, 89bio no longer issues independent news releases. Updates regarding the former 89bio pipeline, including BIO89-100 development, would be communicated through Roche's investor relations channels.
89bio, Inc. (Nasdaq: ETNB) has announced the pricing of its public offering of 16,923,077 shares of common stock at $16.25 per share, which will raise approximately $275 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 2,538,461 shares. The offering is expected to close around March 28, 2023, subject to customary conditions. BofA Securities, SVB Securities, and Evercore ISI are acting as lead book-running managers. 89bio focuses on innovative therapies for liver and cardio-metabolic diseases, with its lead candidate targeting non-alcoholic steatohepatitis (NASH).
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced a public offering of $200 million in common stock or pre-funded warrants. The offering includes a 30-day option for underwriters to purchase an additional $30 million. Proceeds will support clinical activities for pegozafermin, focusing on liver and cardio-metabolic diseases. The offering is subject to market conditions. BofA Securities, SVB Securities, and Evercore ISI are the book-running managers. The company emphasizes that this press release is not an offer to sell securities, as per SEC regulations.
89bio, Inc. (ETNB) announced positive results from its Phase 2b ENLIVEN trial of pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial demonstrated statistically significant improvements in fibrosis and NASH resolution, with the 44mg Q2W and 30mg QW doses achieving placebo-adjusted effect sizes of 20% and 19% for fibrosis improvement, and 24% and 21% for NASH resolution, respectively. The study's results support progression to Phase 3 trials, highlighting pegozafermin’s potential as a differentiated treatment for NASH. The company’s rigorous methodology adds credibility to the findings.
89bio, a clinical-stage biopharmaceutical company, reported significant advancements in its late-stage development program for pegozafermin. Key updates include topline results from the ENLIVEN Phase 2b trial for NASH, anticipated in Q1 2023, and FDA feedback supporting a Phase 3 program for severe hypertriglyceridemia (SHTG), with trials set to begin in Q2 2023. Financially, the company held $188.2 million in cash as of December 31, 2022, a rise from $150.7 million in 2021. However, net losses increased to $102 million for the year, driven by higher R&D and G&A expenses.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
